


I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being electronically filed via EFS-Web with the United States Patent and Trademark Office on the date shown below.

Dated: September 20, 2006

Signature:   
(Michelle Z. Bielunis)

Docket No.: 22956-235  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Alexander M. Harmon et al.

Application No.: 10/729,046

Filed: December 5, 2003

For: VIABLE TISSUE REPAIR IMPLANTS AND  
METHODS OF USE

Confirmation No.: 9312

Art Unit: 3738

Examiner: Alvin J. Stewart

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. These documents were cited in an Examiner's Report that was presented during the prosecution of Australian Patent Application No. 2004226996, which is related to the above-referenced application.

Applicant submits herewith copies of non-patent/literature documents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be

construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Notice of Allowance (37 CFR 1.97(c)). Accordingly, payment in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) has been made via credit card. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 141449, under Order No. 022956-0235.

Dated: September 20, 2006

Respectfully submitted,

By   
Michelle Z. Bielunis  
Registration No.: 57,477  
NUTTER MCCLENNEN & FISH LLP  
World Trade Center West  
155 Seaport Boulevard  
Boston, Massachusetts 02210-2604  
(617) 439-2000  
(617) 310-9000 (Fax)  
Attorney for Applicant